Effects of GSK3640254 on the Single-Dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Fipravirimat (Primary) ; Caffeine; Digoxin; Flurbiprofen; Metoprolol; Midazolam; Montelukast; Omeprazole; Pravastatin
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
Most Recent Events
- 23 Feb 2023 Results assessing pharmacokinetics of GSK3640254 and a Metabolic Probe Cocktail in Healthy Participants published in the British Journal of Clinical Pharmacology
- 13 Apr 2021 Status changed from recruiting to completed.
- 17 Sep 2020 Planned End Date changed from 16 Oct 2020 to 15 Apr 2021.